Biogen Idec, Inc.

Genentech, Inc.

Biogen, Incorporated

Antonio J Grillo-Lopez

Christine A White

John G Curd

Lori Kunkel

Susan Desmond-Hellmann

John E Leonard

Lori A Kunkel

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.

Treatment of diffuse large-cell lymphoma with anti-CD20 antibody

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody

The present invention concerns treatment of pemphigus with an antibody which binds to CD20.

Treatment of pemphigus

This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.

Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.

Treatment of vasculitis

Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.

Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies

Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Antonio J Grillo-Lopez